tradingkey.logo

Quantum BioPharma Ltd

QNTM
4.200USD
+0.280+7.14%
Handelsschluss 02/06, 16:00ETKurse um 15 Minuten verzögert
16.03MMarktkapitalisierung
VerlustKGV TTM

Quantum BioPharma Ltd

4.200
+0.280+7.14%

mehr Informationen über Quantum BioPharma Ltd Unternehmen

Quantum BioPharma Ltd. is a Canada-based biopharmaceutical company. The Company is engaged in building a portfolio of assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., it is focused on the research and development of its lead compound, Lucid-MS, which is a patented new chemical entity to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis. The Company has also licensed unbuzzd, a formulation of natural ingredients, vitamins, and minerals to help with liver and brain function for the purposes of quickly relieving individuals from the effects of alcohol consumption. It maintains a portfolio of strategic investments through its wholly owned subsidiary, FSD Strategic Investments Inc., which represents loans secured by residential or commercial property.

Quantum BioPharma Ltd Informationen

BörsenkürzelQNTM
Name des UnternehmensQuantum Biopharma Ltd
IPO-datumMay 29, 2018
CEOKotra (Lakshmi P)
Anzahl der mitarbeiter- -
WertpapierartOrdinary Share
GeschäftsjahresendeMay 29
Addresse55 University Ave. , Suite 1003
StadtTORONTO
BörseNASDAQ OMX - NASDAQ BASIC
LandCanada
PostleitzahlM5J 2H7
Telefon14168548884
Websitehttps://www.quantumbiopharma.com/
BörsenkürzelQNTM
IPO-datumMay 29, 2018
CEOKotra (Lakshmi P)

Führungskräfte von Quantum BioPharma Ltd

Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Zeeshan Saeed
Mr. Zeeshan Saeed
Executive Co-Chairman of the Board, President, Chief Executive Officer
Executive Co-Chairman of the Board, President, Chief Executive Officer
118.41K
+300.00%
Mr. Donal Carroll, CPA
Mr. Donal Carroll, CPA
Chief Financial Officer
Chief Financial Officer
90.41K
+7692.00%
Mr. Anthony Durkacz
Mr. Anthony Durkacz
Co-Executive Chairman of the Board
Co-Executive Chairman of the Board
29.11K
-77647.00%
Mr. Lawrence (Larry) Latowsky
Mr. Lawrence (Larry) Latowsky
Independent Director
Independent Director
--
--
Mr. Adnan Bashir
Mr. Adnan Bashir
Independent Director
Independent Director
--
--
Dr. Lakshmi P. Kotra, Ph.D.
Dr. Lakshmi P. Kotra, Ph.D.
Chief Executive Officer of Lucid, Director, President of FSD Biosciences and CEO of FSD Australia
Chief Executive Officer of Lucid, Director, President of FSD Biosciences and CEO of FSD Australia
--
--
Mr. Joseph L. Romano
Mr. Joseph L. Romano
Director
Director
--
--
Dr. Eric Hoskins, M.D.
Dr. Eric Hoskins, M.D.
Independent Director
Independent Director
--
--
Mr. Michael (Zappy) Zapolin
Mr. Michael (Zappy) Zapolin
Independent Director
Independent Director
--
--
Dr. Andrzej Chruscinski, M.D., Ph.D.
Dr. Andrzej Chruscinski, M.D., Ph.D.
Vice President - Clinical and Scientific Affairs
Vice President - Clinical and Scientific Affairs
--
-462.00%
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Zeeshan Saeed
Mr. Zeeshan Saeed
Executive Co-Chairman of the Board, President, Chief Executive Officer
Executive Co-Chairman of the Board, President, Chief Executive Officer
118.41K
+300.00%
Mr. Donal Carroll, CPA
Mr. Donal Carroll, CPA
Chief Financial Officer
Chief Financial Officer
90.41K
+7692.00%
Mr. Anthony Durkacz
Mr. Anthony Durkacz
Co-Executive Chairman of the Board
Co-Executive Chairman of the Board
29.11K
-77647.00%
Mr. Lawrence (Larry) Latowsky
Mr. Lawrence (Larry) Latowsky
Independent Director
Independent Director
--
--
Mr. Adnan Bashir
Mr. Adnan Bashir
Independent Director
Independent Director
--
--
Dr. Lakshmi P. Kotra, Ph.D.
Dr. Lakshmi P. Kotra, Ph.D.
Chief Executive Officer of Lucid, Director, President of FSD Biosciences and CEO of FSD Australia
Chief Executive Officer of Lucid, Director, President of FSD Biosciences and CEO of FSD Australia
--
--

Umsatzaufteilung

Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Nach Geschäftsbereich
Nach Region
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.

Aktionärsstatistik

Aktualisiert: Fri, Feb 6
Aktualisiert: Fri, Feb 6
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Malone Wealth Ventures LLC
9.78%
Saeed (Zeeshan)
3.08%
Carroll (Donal)
2.35%
Lynch (Terrence)
1.34%
AdvisorShares Investments, LLC
0.97%
Andere
82.48%
Aktionäre
Aktionäre
Anteil
Malone Wealth Ventures LLC
9.78%
Saeed (Zeeshan)
3.08%
Carroll (Donal)
2.35%
Lynch (Terrence)
1.34%
AdvisorShares Investments, LLC
0.97%
Andere
82.48%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor
11.35%
Individual Investor
8.48%
Corporation
0.37%
Research Firm
0.09%
Andere
79.71%

Institutionelle Beteiligung

Aktualisiert: Thu, Jan 1
Aktualisiert: Thu, Jan 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q4
42
1.11M
29.06%
+169.60K
2025Q3
40
1.17M
30.70%
+254.90K
2025Q2
50
1.04M
35.99%
+612.85K
2025Q1
50
413.46K
17.05%
-229.58K
2024Q4
44
604.87K
28.35%
+138.76K
2024Q3
45
583.17K
30.09%
+414.87K
2024Q2
43
126.91K
14.87%
-21.03K
2024Q1
47
105.72K
14.06%
-57.49K
2023Q4
49
159.35K
26.32%
+20.22K
2023Q3
52
164.58K
27.23%
+48.13K
Mehr Anzeigen

Aktionärsaktivitäten

Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Malone Wealth Ventures LLC
1.05M
27.25%
+217.43K
+26.20%
Sep 06, 2025
Saeed (Zeeshan)
118.41K
3.08%
+300.00
+0.25%
Aug 14, 2025
Carroll (Donal)
90.41K
2.35%
+7.69K
+9.30%
Apr 03, 2025
Lynch (Terrence)
51.42K
1.34%
+51.42K
--
Aug 14, 2025
AdvisorShares Investments, LLC
37.24K
0.97%
+247.00
+0.67%
Sep 30, 2025
Kotra (Lakshmi)
29.57K
0.77%
--
--
Aug 14, 2025
Durkacz (Anthony)
29.11K
0.76%
-77.65K
-72.73%
Oct 29, 2025
Marex Group plc
13.44K
0.35%
+13.44K
--
Sep 30, 2025
Saeed (Rehan)
6.79K
0.18%
-2.15K
-24.09%
Dec 31, 2024
Xorax Family Trust
6.79K
0.18%
--
--
Dec 10, 2025
Mehr Anzeigen

Verbundene ETFs

Aktualisiert: Tue, Dec 2
Aktualisiert: Tue, Dec 2
Name
Anteil
AdvisorShares Psychedelics ETF
6.05%
AdvisorShares Psychedelics ETF
Anteil6.05%

Dividende

In den vergangenen 5 Jahren wurden insgesamt 0.00 USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten

Aktien-Split

Datum
Ex-Dividendentag
Art
Verhältnis
Aug 12, 2024
Merger
65→1
Aug 12, 2024
Merger
65→1
Aug 12, 2024
Merger
65→1
Aug 12, 2024
Merger
65→1
Datum
Ex-Dividendentag
Art
Verhältnis
Aug 12, 2024
Merger
65→1
Aug 12, 2024
Merger
65→1
Aug 12, 2024
Merger
65→1
Aug 12, 2024
Merger
65→1
KeyAI